0001516513-22-000070.txt : 20220804 0001516513-22-000070.hdr.sgml : 20220804 20220804163910 ACCESSION NUMBER: 0001516513-22-000070 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220804 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Doximity, Inc. CENTRAL INDEX KEY: 0001516513 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING SERVICES [7371] IRS NUMBER: 272485512 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40508 FILM NUMBER: 221137292 BUSINESS ADDRESS: STREET 1: 500 THIRD STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (650) 549-4330 MAIL ADDRESS: STREET 1: 500 THIRD STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 8-K 1 docs-20220804.htm 8-K docs-20220804

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 4, 2022
Doximity, Inc.
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
500 3rd St.
Suite 510
San Francisco, CA 94107
(Address of principal executive offices, including zip code)
(650) 549-4330
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, $0.001 par value per shareDOCSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 – Results of Operations and Financial Condition
On August 4, 2022, Doximity, Inc. (“Doximity”) issued a press release announcing its financial results for its fiscal quarter ended June 30, 2022. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.
The information provided in this Item 2.02 of this Current Report on Form 8-K, and the Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 5.02 – Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
(b) Director Resignation
On August 2, 2022, Gilbert Kliman, M.D. informed the board of directors (the "Board") of Doximity of his intention to step down from his role as a director on the Board, including his membership of the nominating and governance committee and the compensation committees of the Board, effective immediately. Dr. Kliman’s departure from the Board is not the result of any disagreement with the Doximity or the Board on any matters relating to Doximity’s operations, policies or practices.
(d) Director Appointment
On August 2, 2022, the Board appointed Phoebe L. Yang Watkin to serve as a Class III director of the Board, filling the vacancy created by the departure of Dr. Kliman from the Board, effective immediately, until the annual meeting of the Doximity’s stockholders to be held in calendar 2024 (the "2024 Annual Meeting"), or until her successor is duly elected and qualified. In addition, Ms. Yang will serve on the nominating and governance committee and the compensation committees of the Board. There is no arrangement or understanding between Ms. Yang and any other persons pursuant to which she was elected as a director. Further, Ms. Yang does not have any family relationships with any director or executive officer of Doximity. Furthermore, there are no related party transactions between Ms. Yang and Doximity that would be required to be reported under Item 404(a) of Regulation S-K. As a non-employee director, Ms. Yang will participate in Doximity’s standard director compensation arrangements pursuant to its non-employee director compensation policy. Under the terms of those compensation arrangements, Ms. Yang will receive, among other things, annual compensation of $30,000 for her services on the Board, an annual compensation of $6,000 for her services on the compensation committee, an annual compensation of $4,000 for her services on the nominating and governance committee and an initial grant of restricted stock units with a value of $350,000, based on the closing price of Doximity’s common stock over the trailing 30-day period ending on the day immediately prior to the effective date of the grants, that vest in equal annual installments over three years, subject to continuous service. The Company has also entered into its standard form of Indemnification Agreement with Ms. Yang in connection with her appointment to the Board.
Item 7.01 – Regulation FD Disclosure
A copy of a press release issued on August 4, 2022 announcing the appointment of Ms. Yang to the Board is furnished herewith as Exhibit 99.2 and is incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K and the accompanying Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 4, 2022
/s/ Anna Bryson
Anna Bryson
Chief Financial Officer

EX-99.1 2 doximity-2022630xex991.htm EX-99.1 Document

Exhibit 99.1
Doximity Announces Fiscal 2023 First Quarter Financial Results
Q1 total revenues of $90.6 million, up 25% year-over-year
Q1 operating cash flow of $44.8 million, up 35% year-over-year
Q1 free cash flow of $42.6 million, up 32% year-over-year

SAN FRANCISCO, Calif., August 4, 2022 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results for the fiscal 2023 first quarter ended June 30, 2022.
“We’re pleased that a record number of physicians, NPs, and PAs used our Doximity Dialer over 200,000 times per workday last quarter to reach and provide more convenient care for their patients,” said Jeff Tangney, co-founder and CEO at Doximity. “We believe this shows that the ‘new normal’ has set in with our users as they adopt a more mobile, hybrid schedule.”
Doximity Appoints Phoebe Yang to its Board of Directors and Launches ESG Site: More information can be found in our press releases at https://investors.doximity.com.
Fiscal 2023 First Quarter Financial Highlights
All comparisons, unless otherwise noted, are to the three months ended June 30, 2021.
Revenue: Revenue of $90.6 million, versus $72.7 million, an increase of 25% year-over-year.
Net income and non-GAAP net income: Net income of $22.4 million, versus $26.3 million, representing a margin of 25%, versus 36%. Non-GAAP net income of $30.8 million, versus $30.6 million, representing a margin of 34%, versus 42%.
Adjusted EBITDA: Adjusted EBITDA of $33.5 million, versus $31.2 million, an increase of 8% year-over-year, representing adjusted EBITDA margins of 37%, versus 43%.
Net income per share and non-GAAP net income per share: Diluted net income per share was $0.10, versus $0.09, while non-GAAP diluted net income per share was $0.14, versus $0.11.
Operating cash flow and free cash flow: Operating cash flow of $44.8 million, versus $33.2 million, and free cash flow of $42.6 million, versus $32.4 million.
Financial Outlook
Doximity is providing guidance for its fiscal second quarter ending September 30, 2022 as follows:
Revenue between $99.5 million and $100.5 million.
Adjusted EBITDA between $40.0 million and $41.0 million.
Doximity is revising its guidance for its fiscal year ending March 31, 2023 as follows:
Revenue between $424.0 million and $432.0 million.
Adjusted EBITDA between $178.0 million and $186.0 million.

Conference Call Information
Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.
About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S medical professionals. The company’s network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Doximity’s mission is to help doctors be more productive so they can provide better care for their patients. For more information, please visit www.doximity.com.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of the COVID-19 pandemic (including the impact to our industry or on our customers’ industries, impact on general economic conditions, and government responses, restrictions, and actions related to the pandemic); (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in the Annual Report on Form 10-K that was filed with the SEC on May 27, 2022. Additional information will be provided in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations Contact:
Perry Gold
Media Contact:
Amanda Cox


(in thousands)
June 30, 2022March 31, 2022
Current assets:
Cash and cash equivalents$110,092 $112,809 
Marketable securities666,162 685,304 
Accounts receivable, net 76,021 81,073 
Prepaid expenses and other current assets18,258 19,439 
Deferred contract costs, current3,610 5,512 
Total current assets874,143 904,137 
Property and equipment, net11,381 8,488 
Deferred income tax assets49,348 48,558 
Operating lease right-of-use assets11,563 1,087 
Intangible assets, net35,430 7,909 
Goodwill67,940 18,915 
Other assets1,126 2,263 
Total assets$1,050,931 $991,357 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$916 $463 
Accrued expenses and other current liabilities25,253 25,270 
Deferred revenue, current93,907 84,907 
Operating lease liabilities, current677 642 
Total current liabilities120,753 111,282 
Deferred revenue, non-current203 78 
Operating lease liabilities, non-current11,092 447 
Contingent earn-out consideration liability, non-current15,668 — 
Other liabilities, non-current1,049 956 
Total liabilities148,765 112,763 
Stockholders' Equity
Preferred stock— — 
Common stock193 192 
Additional paid-in capital715,282 702,589 
Accumulated other comprehensive loss(17,925)(15,294)
Retained earnings204,616 191,107 
Total stockholders' equity902,166 878,594 
Total liabilities and stockholders’ equity$1,050,931 $991,357 


(in thousands, except per share data)
Three Months Ended June 30,
Revenue$90,639 $72,669 
Cost of revenue(1)
13,077 7,986 
Gross profit77,562 64,683 
Operating expenses(1):
Research and development19,022 13,241 
Sales and marketing28,134 19,371 
General and administrative8,724 7,196 
Total operating expenses55,880 39,808 
Income from operations21,682 24,875 
Other income, net804 45 
Income before income taxes22,486 24,920 
Provision for (benefit from) income taxes103 (1,402)
Net income$22,383 $26,322 
Undistributed earnings attributable to participating securities— (15,581)
Net income attributable to Class A and Class B common stockholders, basic and diluted$22,383 $10,741 
Net income per share attributable to Class A and Class B common stockholders:
Basic$0.12 $0.12 
Diluted$0.10 $0.09 
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:
Basic192,947 87,599 
Diluted214,954 114,920 
(1) Costs and expenses include share-based compensation expenses as follows:
Three Months Ended June 30,
Cost of revenue$2,122 $268 
Research and development2,552 970 
Sales and marketing3,074 1,028 
General and administrative1,758 2,861 
Total stock-based compensation expense$9,506 $5,127 

(in thousands)
Three Months Ended June 30,
Cash flows from operating activities
Net income$22,383 $26,322 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization2,370 1,153 
Deferred income taxes105 — 
Stock-based compensation, net of amounts capitalized9,506 5,127 
Non-cash lease expense401 283 
Amortization of premium on marketable securities, net1,455 297 
Loss on sale of marketable securities37 — 
Amortization of deferred contract costs2,767 3,204 
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable5,533 4,421 
Prepaid expenses and other assets1,246 (2,858)
Deferred contract costs(866)(1,492)
Accounts payable, accrued expenses and other liabilities(6,109)(2,257)
Deferred revenue6,152 (461)
Operating lease liabilities(198)(471)
Net cash provided by operating activities44,752 33,175 
Cash flows from investing activities
Cash paid for acquisition(53,500)— 
Purchases of property and equipment(710)(41)
Internal-use software development costs(1,415)(771)
Purchases of marketable securities(8,870)(67,375)
Maturities of marketable securities8,271 10,764 
Sales of marketable securities14,724 — 
Net cash used in investing activities(41,500)(57,423)
Cash flows from financing activities
Proceeds from issuance of common stock upon initial public offering after deducting underwriting discounts and commissions— 553,905 
Proceeds from issuance of common stock upon exercise of stock options and common stock warrants3,014 2,737 
Taxes paid related to net share settlement of equity awards(109)— 
Repurchase of common stock(8,874)(2,698)
Payments of deferred offering costs— (1,768)
Net cash provided by (used in) financing activities(5,969)552,176 
Net increase (decrease) in cash and cash equivalents(2,717)527,928 
Cash and cash equivalents, beginning of period112,809 66,393 
Cash and cash equivalents, end of period
$110,092 $594,321 


Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:
Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of stock-based compensation expense, amortization of acquired intangible assets, change in fair value of contingent earn-out consideration liability, and expenses associated with acquisitions from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.
We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.
Key Business Metrics1
Net revenue retention rate: We calculate net revenue retention rate by taking the trailing 12-month (“TTM”) subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods and reflects customer renewals, expansion, contraction, and churn.
Customers with trailing 12-month subscription revenue greater than $100,000: We calculate the number of customers with TTM product revenue greater than $100,000 by counting the number of customers that contributed more than $100,000 in subscription revenue in the TTM period. The number of customers with TTM subscription-based revenue of at least $100,000 is a key indicator of the scale of our business. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity.
1 The metrics exclude the impact of the AMiON acquisition, which closed on April 1, 2022, including customers of and subscription revenue generated from the AMiON on-call scheduling and messaging application and was immaterial to the periods presented.

Reconciliation of GAAP to Non-GAAP Financial Measures
The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:
Three Months Ended June 30,
(in thousands, except percentages)
Net income$22,383 $26,322 
Adjusted to exclude the following:
Acquisition and other related expenses30 — 
Stock-based compensation9,506 5,127 
Depreciation and amortization2,370 1,153 
Provision for (benefit from) income taxes103 (1,402)
Change in fair value of contingent earn-out consideration liability(54)— 
Other income, net(804)(45)
Adjusted EBITDA$33,534 $31,155 
Revenue$90,639 $72,669 
Net income margin25 %36 %
Adjusted EBITDA margin37 %43 %

Three Months Ended June 30,
(in thousands)
Net cash provided by operating activities$44,752 $33,175 
Purchases of property and equipment(710)(41)
Internal-use software development costs(1,415)(771)
Free cash flow$42,627 $32,363 
Other cash flow components:
Net cash used in investing activities$(41,500)$(57,423)
Net cash provided by (used in) financing activities$(5,969)$552,176 

Three Months Ended June 30,
(in thousands, except percentages)
GAAP cost of revenue$13,077 $7,986 
Adjusted to exclude the following:
Stock-based compensation(2,122)(268)
Amortization of acquired intangibles(137)— 
Non-GAAP cost of revenue$10,818 $7,718 
GAAP gross profit$77,562 $64,683 
Adjusted to exclude the following:
Stock-based compensation2,122 268 
Amortization of acquired intangibles137 — 
Non-GAAP gross profit$79,821 $64,951 
GAAP gross margin86 %89 %
Non-GAAP gross margin88 %89 %
GAAP research and development expense$19,022 $13,241 
Adjusted to exclude the following:
Stock-based compensation(2,552)(970)
Non-GAAP research and development expense$16,470 $12,271 
GAAP sales and marketing expense$28,134 $19,371 
Adjusted to exclude the following:
Stock-based compensation(3,074)(1,028)
Amortization of acquired intangibles(1,063)(265)
Change in fair value of contingent earn-out consideration liability54 — 
Non-GAAP sales and marketing expense$24,051 $18,078 
GAAP general and administrative expense$8,724 $7,196 
Adjusted to exclude the following:
Acquisition and other related expenses(30)— 
Stock-based compensation(1,758)(2,861)
Non-GAAP general and administrative expense$6,936 $4,335 
GAAP operating expense$55,880 $39,808 
Adjusted to exclude the following:
Acquisition and other related expenses(30)— 
Stock-based compensation(7,384)(4,859)
Amortization of acquired intangibles(1,063)(265)
Change in fair value of contingent earn-out consideration liability54 — 
Non-GAAP operating expense$47,457 $34,684 
GAAP operating income$21,682 $24,875 
Adjusted to exclude the following:
Acquisition and other related expenses30 — 
Stock-based compensation9,506 5,127 
Amortization of acquired intangibles1,200 265 
Change in fair value of contingent earn-out consideration liability(54)— 
Non-GAAP operating income$32,364 $30,267 

Three Months Ended June 30,
(in thousands, except per share data and percentages)
GAAP net income$22,383 $26,322 
Adjusted to exclude the following:
Acquisition and other related expenses30 — 
Stock-based compensation9,506 5,127 
Amortization of acquired intangibles1,200 265 
Change in fair value of contingent earn-out consideration liability(54)— 
Income tax effect of non-GAAP adjustments (1)
Non-GAAP net income$30,822 $30,582 
Non-GAAP net income margin34 %42 %
GAAP undistributed earnings attributable to participating securities$— $(15,581)
Impact on undistributed earnings attributable to participating securities due to non-GAAP adjustments— (1,947)
Non-GAAP undistributed earnings attributable to participating securities$— $(17,528)
Non-GAAP net income$30,822 $30,582 
Non-GAAP undistributed earnings attributable to participating securities— (17,528)
Non-GAAP net income attributable to Class A and Class B stockholders, basic and diluted$30,822 $13,054 
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:
Basic192,947 87,599 
Diluted214,954 114,920 
Non-GAAP net income per share attributable to Class A and Class B stockholders:
Basic$0.16 $0.15 
Diluted$0.14 $0.11 
(1) For the three months ended June 30, 2022 and 2021, management used an estimated annual effective non-GAAP tax rate of 21.0%.
EX-99.2 3 exhibit992-boardappointment.htm EX-99.2 Document

Exhibit 99.2
Doximity Appoints Phoebe Yang to Its Board of Directors
Experienced Director and Executive Brings Health System and Cloud Expertise
SAN FRANCISCO, August 4, 2022 – Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced the appointment of Phoebe L. Yang to its Board of Directors. Ms. Yang has been General Manager at Amazon Web Services, Healthcare, and a member of the board of directors for CommonSpirit Health, one of the largest U.S. health systems. Ms. Yang is a long-time member of the Council on Foreign Relations, and has served as an appointee in two Presidential Administrations. In 2021, she was named one of Modern Healthcare’s Top 100 Most Influential People in Healthcare and one of Fierce Healthcare’s Top 10 Women of Influence.
“We’re delighted to welcome Phoebe to our Board,” said Jeff Tangney, co-founder and CEO of Doximity. “Phoebe is a rare ‘two-sport’ leader, well-versed in both healthcare and technology. Her industry insight and go-to-market expertise will be invaluable as we continue to grow and serve all 20 of the top 20 health systems. We’re delighted to work with Phoebe to put technology to work for doctors.”
As a Board member, Ms. Yang will provide strategic guidance to Doximity as it continues to innovate its clinical productivity tools and build the “physician cloud” for U.S. health systems. In addition to her work at AWS, Healthcare, Ms. Yang has served in C-suite or executive leadership roles at four publicly traded companies. She has also served on the board of directors for Providence St. Joseph Health, as Chief Strategy Officer and Chief Architect for Population Health at Ascension, and as Lead Expert on Health IT and Broadband Task Forces for the White House.
“I’m excited to join Doximity’s Board of Directors during a time of significant growth and opportunity,” said Yang. “Doximity’s ‘physicians first’ philosophy helps make doctors more productive so they can improve patient experiences and outcomes – there is no more important mission in healthcare today. I look forward to working with Jeff Tangney, one of the most impressive CEOs in digital health, his exceptional leadership team, and Doximity’s impressive Board in leveraging technology to enable and support clinicians and their patients.”
About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company’s network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Doximity’s mission is to help doctors be more productive so they can provide better care for their patients. For more information visit Doximity.com.

EX-101.SCH 4 docs-20220804.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 docs-20220804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Tax Identification Number Entity Tax Identification Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Local Phone Number Local Phone Number Written Communications Written Communications Cover [Abstract] Document Type Document Type Entity Ex Transition Period Entity Ex Transition Period Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 docs-20220804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Aug. 04, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 04, 2022
Entity Registrant Name Doximity, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40508
Entity Tax Identification Number 27-2485512
Entity Address, Address Line One 500 3rd St.
Entity Address, Address Line Two Suite 510
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94107
City Area Code 650
Local Phone Number 549-4330
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, $0.001 par value per share
Trading Symbol DOCS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001516513
Amendment Flag false
XML 8 docs-20220804_htm.xml IDEA: XBRL DOCUMENT 0001516513 2022-08-04 2022-08-04 0001516513 false 8-K 2022-08-04 2022-08-04 Doximity, Inc. DE 001-40508 27-2485512 500 3rd St. Suite 510 San Francisco CA 94107 650 549-4330 false false false false Class A common stock, $0.001 par value per share DOCS NYSE true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.doximity.com/role/Cover Cover Cover 1 false false All Reports Book All Reports docs-20220804.htm docs-20220804.xsd docs-20220804_lab.xml docs-20220804_pre.xml doximity-2022630xex991.htm exhibit992-boardappointment.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "docs-20220804.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "docs-20220804.htm" ] }, "labelLink": { "local": [ "docs-20220804_lab.xml" ] }, "presentationLink": { "local": [ "docs-20220804_pre.xml" ] }, "schema": { "local": [ "docs-20220804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "docs", "nsuri": "http://www.doximity.com/20220804", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "docs-20220804.htm", "contextRef": "i7ab568f25698469691a255eac66c1ecf_D20220804-20220804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.doximity.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "docs-20220804.htm", "contextRef": "i7ab568f25698469691a255eac66c1ecf_D20220804-20220804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.doximity.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001516513-22-000070-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001516513-22-000070-xbrl.zip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end